Picropodophyllin (PPP)

For research use only. Not for use in humans.

目录号:S7668 别名: AXL1717 中文名称:鬼臼毒素

Picropodophyllin (PPP) Chemical Structure

CAS No. 477-47-4

Picropodophyllin (PPP, AXL1717)是一种选择性IGF-1R抑制剂,IC50为1 nM。它对IGF-IR具有高选择性,对IR的酪氨酸磷酸化或FGF-R、PDGF-R、EGF-R没有抑制作用。Picropodophyllin (PPP)可诱导凋亡并具有抗肿瘤活性。

规格 价格 库存 购买数量  
RMB 810.01 现货
RMB 2422.47 现货
RMB 5701.86 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Picropodophyllin (PPP)发表文献26篇:

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Picropodophyllin (PPP, AXL1717)是一种选择性IGF-1R抑制剂,IC50为1 nM。它对IGF-IR具有高选择性,对IR的酪氨酸磷酸化或FGF-R、PDGF-R、EGF-R没有抑制作用。Picropodophyllin (PPP)可诱导凋亡并具有抗肿瘤活性。
靶点
IGF-1R [1]
(Cell-free assay)
1 nM
体外研究

在完整细胞中,PPP有效抑制IGF-1刺激的IGF-1R,Akt (Ser 473)和 Erk1/2磷酸化。在培养的IGF-1R 阳性肿瘤细胞中,Picropodophyllin特异性抑制细胞生长,并诱导细胞凋亡。[1] Picropodophyllin通过进一步降低细胞活性并增强细胞凋亡,协同使HMCL,原代人MM 和小鼠5T33MM细胞对ABT-737 和 ABT-199更敏感。[3] Picropodophyllin 和sorafenib协同抑制肝细胞癌的增殖和活性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A-549 (human lung carcinoma) neoplastic cell line NHrMZ5pEgXSxdH;4bYPDqGG|c3H5 NHnxZ2dKdiC4aYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCC2aHWgRU02PDliKHj1cYFvKGy3bnegZ4Fz[2mwb33hLUBv\W:ybHHzeIlkKGOnbHygcIlv\SxiSVO1NF03OCCwTR?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDl6ME[4Nkc,OTR7OEC2PFI9N2F-
P-388 neoplastic cell line MU\DfZRwfG:6aXRCpIF{e2G7 NHLifoZKdiC4aYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCC2aHWgVE0{QDhiKH\yc40hTEKDL{KgcY92e2VrIH7lc5Bt[XO2aXOgZ4VtdCCuaX7lMEBKSzVyPU[wJI5O NV7i[pZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS5PFA3QDJpPkG0PVgxPjh{PD;hQi=>
HT-29 (human colon carcinoma) neoplastic cell line NX7aXYNkS3m2b4TvfIlkyqCjc4PhfS=> NF7SZ2dKdiC4aYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCC2aHWgTHQuOjliKHj1cYFvKGOxbH;uJINiemOrbn;tZUkhdmWxcHzhd5Rq[yClZXzsJIxqdmVuIFnDOVA:PjBibl2= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDl6ME[4Nkc,OTR7OEC2PFI9N2F-
amnion cells MV;BcpRqfmm{YXygZZN{[Xl? NXqw[lJQSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUFOYMTDpcoZm[3SnZDDpckBpfW2jbjDwdolu[XK7IHHtcolwdiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW|LXnu[JVk\WRicHH0bI9o\W6rYzDl[oZm[3RuIFHjeIl3cXS7IE2gNU46KM7:TT6= M4XONlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6M{SxO|koRjl6M{SxO|k9N2F-
P388 MnK2R5l1d3SxeHnjbZR6KGG|c3H5 NVvWOpNYS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhWDN6ODDj[YxteyxiSVO1NEA:KDZizszNMi=> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84Pjd|OUOxK|44Pjd|OUOxQE9iRg>?
A549 MorJR5l1d3SxeHnjbZR6KGG|c3H5 MorER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{whUUN3MDC9JFYh|ryPLh?= MoLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwPzZ5M{mzNUc,PzZ5M{mzNVww[T5?
HT-29 MXnDfZRwfG:6aXPpeJkh[XO|YYm= M4DHW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{NCCLQ{WwJF0hPiEQvF2u MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84Pjd|OUOxK|44Pjd|OUOxQE9iRg>?
TC32 NIXqU4pyUFSVIHHzd4F6 M{XxVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| Mlq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY NVy5Xm5SeUiWUzDhd5NigQ>? M{HqTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 MVHxTHRUKGG|c3H5 Mk\RdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NX3kXYFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MoGwdWhVWyCjc4PhfS=> M{HXcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NIHYeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NVLvWWNyeUiWUzDhd5NigQ>? M2HDcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz M{f3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NXfrZlBNeUiWUzDhd5NigQ>? M4\hR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NUfFeZJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 NYj1UlRVeUiWUzDhd5NigQ>? MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| M1;MWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 MnnjdWhVWyCjc4PhfS=> NEK2dnhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= NE\DblM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 NEnkVXVyUFSVIHHzd4F6 NU\IPVMzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz NWf4NpVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NVSxXJFbeUiWUzDhd5NigQ>? NGPwSZdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 M1HjOpFJXFNiYYPzZZk> MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> M{e3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NYrnXI9ueUiWUzDhd5NigQ>? M4TiR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? NWDoZ3VFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 M{TGepFJXFNiYYPzZZk> MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=> MoPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 MVHxTHRUKGG|c3H5 NH7Le4FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>? MlnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY MYfxTHRUKGG|c3H5 M2LLXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGRCV1liY3XscJM> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 NYLqbGRWeUiWUzDhd5NigQ>? M2TvdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN? M2nieFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 NYP5VHVZeUiWUzDhd5NigQ>? MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsdy=> NUfTR3k4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 NIfrTXlyUFSVIHHzd4F6 MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR|MzKGOnbHzz Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) Mmr2dWhVWyCjc4PhfS=> MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=> NWLGe3JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS NIG2fppyUFSVIHHzd4F6 M3TrVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M{jVU5FJXFNiYYPzZZk> NFHMUZdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=> M4L0R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 MoO1dWhVWyCjc4PhfS=> NUjae3JzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| MmDEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IGFR1 / p-AKT / p-ERK ; 

PubMed: 22363814     


A) IGFR1 Y1136 Phosphorylation was inhibited with picropodophyllin (PPP). A random pharmacologic control drug, PHA, had no effect on IGFR1 phosphorylation. B) PPP treatment significantly decreases downstream AKT S473 phosphorylation and ERK p44/p42 phosphorylation (C). * denotes P<0.05 compared to control. (n = 3).

22363814
Growth inhibition assay
Cell viability; 

PubMed: 22159423     


Effect of PPP on cell viability. Left panel, cells were treated with 0.5 μM PPP and counted manually in quadruplicates using trypan blue exclusion resulting in number of viable adherent and suspension cells, respectively. Right panel, in parallel, the number of dead adherent and suspension cells was counted and viability calculated and expressed as mean % viable cells ± SD. All experiments were performed three times and one representative is shown.

22159423
体内研究 在异种移植人ES-1,BE,和PC3的SCID小鼠体内,Picropodophyllin (20 mg/kg/12 h, i.p.)引起完全的肿瘤退化。[1]在5T33MM小鼠模型中,Picropodophyllin也表现出有效的抗肿瘤活性,并使存活率显著增加。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

体外酪氨酸激酶试验。:

IGF-1R催化的pTG底物磷酸化测定使用96孔板酪氨酸激酶试剂盒进行。我们使用重组表皮生长因子受体,HEPG2免疫沉淀物IR,P6细胞免疫沉淀物IGF-1R,以及来自P6 (代表“非-IGF-1R 酪氨酸激酶”)的IGF-1R免疫沉淀上清液。用所需化合物将受体在激酶缓冲液[50 mM HEPES 缓冲液(pH 7.4),20 mM MgCl2,0.1 MnCl2,和0.2 Na3VO4]中处理30分钟,激酶反应通过加入ATP激活。磷酸化聚合体底物用与辣根过氧化物酶共轭的磷酸酪氨酸特异性单克隆抗体,克隆PT-66探测。通过辣根过氧化物酶底物邻苯二胺二盐酸化物显色,并通过分光光度法(ELISA 阅读器)定量。IGF-1R酪氨酸自磷酸化通过夹心ELISA法进行分析。简而言之,96孔板用1微克/孔的IGF-1R β亚型抗体涂覆,在4℃下培养过夜。板用1% BSA在PBS Tween中封存1小时,然后将来自P6细胞系的总蛋白裂解物以80微克/孔加入。使用来自R细胞系的总蛋白裂解物作为阴性对照。将研究的化合物加入不含ATP的酪氨酸激酶缓冲液,在室温下进行30分钟,再用ATP活化激酶。激酶测定使用Sigma 试剂盒(如上)进行。分光光度法后,使用软件程序的REGRESSION函数测定抑制剂的IC50值。
细胞实验:

[1]

- 合并
  • Cell lines: 黑色素瘤细胞(FM 55,SK-MEL-28,SK-MEL-5,C8161,DFB,DFW 和 AA),肉瘤细胞(RD-ES),乳腺癌细胞(MCF 7),前列腺癌细胞(PC3),肝癌细胞(HepG2)和胚胎小鼠成纤维细胞(P6 和 R-)
  • Concentrations: ~15 μM
  • Incubation Time: 48小时
  • Method:

    测定使用细胞增殖试剂盒II,基于黄色四唑鎓盐2,3-双[2-甲氧基-4-硝基-5-磺苯基] -2H-四唑鎓-5-羧酰苯胺内盐在橙色甲瓒染料中被活细胞呼吸链改变色度的原理进行。所有参照标准和实验以一式三份进行。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 负荷表达IGF-1R,或 R- v-src (IGF-1R 阴性) 和 P12 (过表达 IGF-1 和 IGF-1R)的 ES-1,BE,或 PC3 异种移植物的SCID小鼠
  • Dosages: 20 mg/kg/12 h
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL warmed (197.87 mM)
Water Insoluble
Ethanol '1 mg/mL warmed

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 414.41
化学式

C22H22O8

CAS号 477-47-4
储存条件 粉状
溶于溶剂
别名 AXL1717

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04433052 Not yet recruiting Behavioral: personalised prevention program (PPP) Coronary Heart Disease Tampere University October 2021 Not Applicable
NCT03646058 Recruiting Drug: Buprenorphine|Drug: Placebo Suicidal Ideation|Major Depressive Episode Centre Hospitalier Universitaire de Nīmes September 2021 Phase 3
NCT04842084 Recruiting Biological: Blood samples Healthy Volunteers Centre Hospitalier Universitaire de Saint Etienne April 23 2021 --
NCT04295928 Recruiting Behavioral: PPP Personalized Pharmaceutical Plan After Transpantation University Hospital Tours|INSERM CIC1415 CHRU de Tours ;INSERM SPHERE U1246|Unité d''Epidémiologie des Données cliniques en Centre-Val de Loire (EpiDcliC)|Unité d''Evaluation Médico-Economique (UEME) October 12 2020 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I am currently setting the conditions for in vivo experiments, how should I reconstitute the drug?

  • 回答:

    Other than DMSO:vegetable oil 10:1 (v/v) cited from reference. We tested another formulation: 4% DMSO+corn oil. S7668 Picropodophyllin (PPP) can be dissolved in it at 5 mg/ml clearly. But after stayed for about 20-30 min, the two phase would separate and wouldn't get together again. So if you are going to use this formulation, please prepare the fresh solution just before use.

免费分装抑制剂

IGF-1R Signaling Pathway Map

相关IGF-1R产品

Tags: 购买Picropodophyllin (PPP) | Picropodophyllin (PPP)供应商 | 采购Picropodophyllin (PPP) | Picropodophyllin (PPP)价格 | Picropodophyllin (PPP)生产 | 订购Picropodophyllin (PPP) | Picropodophyllin (PPP)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID